These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 21811962)

  • 1. Paget's disease of bone and calcium homeostasis: focus on bisphosphonate treatment.
    Polyzos SA; Anastasilakis AD; Makras P; Terpos E
    Exp Clin Endocrinol Diabetes; 2011 Oct; 119(9):519-24. PubMed ID: 21811962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bisphosphonate therapy for Paget's disease in a patient with hypoparathyroidism: profound hypocalcemia, rapid response, and prolonged remission.
    Stuckey BG; Lim EM; Kent GN; Ward LC; Gutteridge DH
    J Bone Miner Res; 2001 Sep; 16(9):1719-23. PubMed ID: 11547843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.
    Abelson A
    Curr Med Res Opin; 2008 Mar; 24(3):695-705. PubMed ID: 18226324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Profound hypocalcemia following effective response to zoledronic acid treatment in a patient with juvenile Paget's disease.
    Polyzos SA; Anastasilakis AD; Litsas I; Efstathiadou Z; Kita M; Arsos G; Moralidis E; Papatheodorou A; Terpos E
    J Bone Miner Metab; 2010 Nov; 28(6):706-12. PubMed ID: 20533067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical management of Paget's disease of bone: indications for treatment and review of current therapies.
    Siris ES; Lyles KW; Singer FR; Meunier PJ
    J Bone Miner Res; 2006 Dec; 21 Suppl 2():P94-8. PubMed ID: 17229018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe hypocalcemia following bisphosphonate treatment in a patient with Paget's disease of bone.
    Whitson HE; Lobaugh B; Lyles KW
    Bone; 2006 Oct; 39(4):954-8. PubMed ID: 16769264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum OPG and RANKL levels before and after intravenous bisphosphonate treatment in Paget's disease of bone.
    Martini G; Gennari L; Merlotti D; Salvadori S; Franci MB; Campagna S; Avanzati A; De Paola V; Valleggi F; Nuti R
    Bone; 2007 Feb; 40(2):457-63. PubMed ID: 16979395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preventive Role of Vitamin D Supplementation for Acute Phase Reaction after Bisphosphonate Infusion in Paget's Disease.
    Merlotti D; Rendina D; Muscariello R; Picchioni T; Alessandri M; De Filippo G; Materozzi M; Bianciardi S; Franci MB; Lucani B; Cenci S; Strazzullo P; Nuti R; Gennari L
    J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31634910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current treatment approaches for Paget's Disease of Bone.
    Brandi ML
    Discov Med; 2010 Sep; 10(52):209-12. PubMed ID: 20875342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteomalacia in a patient with Paget's bone disease treated with long-term etidronate.
    Hoppé E; Masson C; Laffitte A; Chappard D; Audran M
    Morphologie; 2012 Aug; 96(313):40-3. PubMed ID: 23022200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple fractures in a woman receiving 24 years of etidronate treatment for Paget's disease.
    Labinson P; Taxel P
    Conn Med; 2007 May; 71(5):269-73. PubMed ID: 17526382
    [No Abstract]   [Full Text] [Related]  

  • 13. A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone.
    Walsh JP; Ward LC; Stewart GO; Will RK; Criddle RA; Prince RL; Stuckey BG; Dhaliwal SS; Bhagat CI; Retallack RW; Kent GN; Drury PJ; Vasikaran S; Gutteridge DH
    Bone; 2004 Apr; 34(4):747-54. PubMed ID: 15050907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisphosphonate-associated osteonecrosis: a clinician's reference to patient management.
    Grewal VS; Fayans EP
    Todays FDA; 2008 Aug; 20(8):38-41, 43-6. PubMed ID: 18767452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risedronate and pamidronate treatment in the clinical management of patients with severe Paget's disease of bone and acquired resistance to bisphosphonates.
    Rendina D; Mossetti G; Viceconti R; Sorrentino M; Nunziata V
    Calcif Tissue Int; 2004 Sep; 75(3):189-96. PubMed ID: 15148558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of Paget's disease of bone.
    Langston AL; Ralston SH
    Rheumatology (Oxford); 2004 Aug; 43(8):955-9. PubMed ID: 15187244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful treatment of resistant Paget's disease of bone with pamidronate.
    Mallette LE
    Arch Intern Med; 1989 Dec; 149(12):2765-7. PubMed ID: 2596945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological therapy of Paget's and other metabolic bone diseases.
    Hosking D
    Bone; 2006 Feb; 38(2 Suppl 2):S3-7. PubMed ID: 16406763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A tale of three diseases of the bone.
    Kannan S; Mahadevan S; Sathya A; Sriram U
    Singapore Med J; 2008 Oct; 49(10):e263-5. PubMed ID: 18946593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of vitamin D deficiency in breast cancer patients on bisphosphonates.
    Wang-Gillam A; Miles DA; Hutchins LF
    Oncologist; 2008 Jul; 13(7):821-7. PubMed ID: 18614589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.